Table 14Percent change in blood loss from baseline in studies of NSAIDs

Author, YearNSAIDComparatorNSAID GroupComparator GroupNSAID vs. Comparator Group
Vargyas et al., 198772MeclofenamatePlacebo−48.9−9.2p<0.0001
Van Elijkeren et al., 199267Mefenamic acidPlacebo−40.0NRNR
Hall et al., 198775Mefenamic acidNaproxen−47.0−46.0NS
Fraser et al., 1981, 198476 ,93Mefenamic acidPlaceboNRNRp<0.001
Reid and Virtanen-Kari,200563Mefenamic acidLNG-IUS−23.0−95.0p<0.001
Bonnar and Sheppard,199666Mefenamic acidTXA−20.0−54.0p<0.05
Bonnar and Sheppard,199666Mefenamic acidEthamsylate−20.00p<0.001
Fraser and McCarron, 199168Mefenamic acidNaproxen−20.0−12.0NS
Fraser and McCarron, 199168Mefenamic acidCOCa−38.0−43.0NS
Cameron et al., 199070Mefenamic acidNorethisterone−24.0−20.0NS
Andersch et al., 198871FlurbiprofenTXA−24.0−53.0p<0.01

COC = combined oral contraceptive; LNG-IUS = levonorgestrel-releasing intrauterine system; TXA = tranexamic acid; NS = nonsignificant

a

30 mcg ethinyl estradiol and 150 mcg levonorgestrel.

From: Results

Cover of Primary Care Management of Abnormal Uterine Bleeding
Primary Care Management of Abnormal Uterine Bleeding [Internet].
Comparative Effectiveness Reviews, No. 96.
Hartmann KE, Jerome RN, Lindegren ML, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.